Abstract 3854: Newly designed nanobioconjugate for direct targeting and systemic treatment of HER2-positive breast cancer

@article{Inoue2010Abstract3N,
  title={Abstract 3854: Newly designed nanobioconjugate for direct targeting and systemic treatment of HER2-positive breast cancer},
  author={S. Inoue and Hui Ding and B. Konda and J. Portilla-Arias and R. Patil and A. Espinoza and S. Rudenkyy and M. Penichet and M. Riley and M. Gates and E. Holler and K. Black and J. Ljubimova},
  journal={Cancer Research},
  year={2010},
  volume={70},
  pages={3854-3854}
}
Objective: We have developed an efficient nanobipolymer drug delivery system Polycefin based on natural-derived biodegradable, non-toxic and non-immunogenic polymalic acid (PMLA) platform. We have shown that Polycefin was able to block brain tumor growth and angiogenesis. Our goal is to engineer the new Polycefin variant for systemic (I.V.) treatment of HER2-positive breast tumors in order to enhance the efficacy of trastuzumab/Herceptin®. Materials and Methods: For in vitro and in vivo… Expand